水产养殖疫苗开发的现代生物技术策略——前景与挑战
本系统综述探讨了基因组学与全基因组测序成本下降为水产养殖现代生物技术疫苗开发带来的机遇与挑战。多数商业水产疫苗仍采用传统方法,而基于表面抗原、重组DNA/mRNA/质粒、新型抗原递送系统、分子佐剂及封装聚合物的生物技术疫苗虽在田间试验中高效,但多处于研发管线或专利阶段,仅少数在高价值鲑科鱼类中获批。
要点
- 水产商业疫苗仍以传统技术为主,给药成本、保护性免疫与安全性是主要挑战。
- 生物技术疫苗(重组DNA/mRNA、VLP、壳聚糖纳米粒等)在田间试验中高效,但多处于研发或专利阶段。
- 仅少数生物技术疫苗获批用于高价值鲑科鱼类,多种重要病原尚无注册疫苗。
核心结论
- 生物技术疫苗在田间试验中证明非常高效,但始终处于研究管线或作为专利存在,仅极少数获批用于高价值鲑科鱼类。
- 若尝试开发新型递送方法、成本效益高的程序并放宽DNA疫苗法规,基于生物技术的疫苗接种可规避水产养殖中新出现的疾病挑战。
研究设计与样本
- 系统综述,描述水产养殖中实施高技术疫苗的前景与挑战。
主要发现
- 多数水产商业疫苗采用传统程序,给药成本、保护性免疫与安全性是主要挑战。
- 基于表面抗原、蛋白/肽/多糖亚单位、重组DNA/mRNA/质粒、新型抗原表达与递送系统(噬菌体颗粒、病毒样颗粒/VLP、重组酵母、黏膜疫苗)、新型分子佐剂(IL-8、IL-12、HSPs)及封装聚合物与多糖(壳聚糖纳米粒、PLGA微胶囊)的疫苗已成功开发。
- 目前商业水产疫苗可用于杀鲑气单胞菌(Aeromonas salmonicida)、杀鲑弧菌(Vibrio salmonicida)、鲁氏耶尔森菌(Yersinia ruckeri)、鳗弧菌(Vibrio anguillarum)、鲶鱼爱德华氏菌(Edwardsiella ictalurid)及某些乙型诺达病毒。
- 尚无注册疫苗可用于其他主要传染病/病原体,如病毒性出血性败血症病毒(VHSV)、病毒性神经坏死病毒(VNN)及某些其他乙型诺达病毒、沟鲶病毒(CCV)、鳃病细菌、分枝杆菌、黄杆菌、爱德华氏菌(Edwardsiella tarda)及某些链球菌。
关键数值与推荐
- 原文未报告具体数值与推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 商业化受限源于水生物种的免疫学缺陷、大规模疫苗接种问题、抗生素与化学药物使用未受监管、基因疫苗法规及商业可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in genomics and the gradual reduction of cost for technologies like whole-genome sequencing have provided exciting opportunities for developing modern biotechnological-based vaccines in aquaculture. This systemic review describes the prospects and challenges of implementing these high-tech vaccines in fish species. The majority of the commercial vaccines in aquaculture utilize conventional procedures for which cost of administration, protective immunity and safety issues are the major challenges. In recent years, more efficient vaccines are being developed by adopting the advances in vaccine technology. Vaccines based on surface antigens, protein/peptide/polysaccharide subunits, recombinant DNA/mRNA/plasmids, novel antigen expression and delivery systems (bacteriophage particles, virus like particles/VLPs, recombinant yeast, mucosal vaccines), novel molecular adjuvants (IL-8, IL-12, HSPs), and encapsulation polymers and polysaccharides like chitosan nanoparticles and PLGA microcapsule were successfully developed. These biotechnology-based vaccines have proved to be very efficient in field trials, but are always in the research pipeline or as patents. Only very few of them are licensed for use, that too, in high-valued fishes like salmonids. Currently, commercial aquaculture vaccines are available for Aeromonas salmonicida, Vibrio salmonicida, Yersinia ruckeri, Vibrio anguillarum, Edwardsiella ictalurid, and for certain Betanodaviruses. Nevertheless, no registered vaccines are available for other major infectious diseases/pathogens such as viral hemorrhagic septicemia virus (VHSV), viral nervous necrosis virus (VNN) and certain other betanodaviruses, channel catfish virus (CCV), gill disease bacteria, mycobacteria, flavobacterium, Edwardsiella tarda, and certain streptococci. Despite the important economic losses that the pathogens cause to aquaculture worldwide, the commercialization of vaccines remains limited due to immunological pitfalls in aquatic species, large-scale vaccination issues, unregulated use of antibiotics and chemicals, gene-based vaccine regulations and commercial viability. If attempts are to be made to develop novel delivery methods, cost-effective procedures, and relaxations in DNA vaccine regulations, biotechnology-based vaccination could circumvent the emerging disease challenges in aquaculture.
引用
- Jose Priya TA, Kappalli S. Modern biotechnological strategies for vaccine development in aquaculture - Prospects and challenges. Vaccine. 2022. PMID: 36088192. doi:10.1016/j.vaccine.2022.08.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。